# OnCo record keynote-966 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-966/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-966", "NCT04003636" ;
  schema:name "KEYNOTE-966"@en ;
  schema:description "A second immunotherapy trial confirmed the modest survival benefit of adding PD-1 blockade to chemotherapy in bile duct cancer."@en ;
  schema:url <https://onco.cc/trials/keynote-966/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04003636>, <https://www.nice.org.uk/guidance/terminated/ta966>, <https://www.nice.org.uk/guidance/terminated/ta966> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2019-09-24" ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/gallbladder/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-966-lancet-2023/> .